Women with advanced or recurring ovarian, peritoneal, or fallopian tube cancer may be eligible to enroll in a new clinical trial offered through Sarasota Memorial’s Kolschowsky Research and Education Institute.
The study, led locally by gynecologic oncology surgeons Beverly Long, MD, and Toni Kilts, DO, with Sarasota Memorial’s First Physicians Group and Brian D. Jellison Cancer Institute, is testing different dosing schedules of the investigational drug Mirvetuximab Soravtansine. The drug targets folate receptor-alpha (FRα), a protein found in high levels on many ovarian, fallopian tube, and primary peritoneal cancer cells.
By focusing on FRα, Mirvetuximab Soravtansine is designed to identify and attack cancer cells more precisely, with reduced impact on nearby healthy cells. The trial aims to measure clinical benefit while exploring dosing regimens that may offer more convenience to patients.
Eligible participants include women with high-grade ovarian, peritoneal, or fallopian tube cancers that no longer respond to platinum-based chemotherapy, whose tumors test positive for FRα, and whose disease has continued to grow or spread after prior treatment.
Locally, the Kolschowsky Institute’s research team will oversee participant enrollment, treatment administration, and monitoring. The Sarasota site is part of a broader national trial evaluating this targeted therapy for hard-to-treat gynecologic cancers.
Those interested in learning more or confirming eligibility can contact the Kolschowsky Institute research team at 941-917-2225 or email researchinstitute@smh.com
